What is ENDRA Life Sciences Inc.'s earnings per share (EPS)?

ENDRA Life Sciences Inc. (NDRA) reported diluted earnings per share of -$8.93 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

ENDRA Life Sciences Inc. (NDRA) Financials

NDRA

FY2025 annual

Net Income -$7.0M +38.9% YoY

EPS (Diluted) -$8.93 YoY not available

Free Cash Flow -$5.2M +29.9% YoY

Operating Cash Flow -$5.2M +30.0% YoY

Market Cap $7.6M as of Oct 13, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 1.2x on $6.3M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Oct 2, 2026 Currency USD FYE December

Newest figures come from the S-4 for Q2 FY2026, filed Oct 2, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NDRA SEC filings page.

This page shows ENDRA Life Sciences Inc. (NDRA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NDRA FY2025 2026-10-10

ENDRA remains externally financed: lower operating losses in FY2025 came alongside much thinner short-term liquidity and continued cash consumption.

Operating cash outflow narrowed from $7.4M in FY2024 to $5.2M in FY2025, but the current ratio fell from 5.7x to 1.3x as current assets contracted. That combination means the improvement in annual cash use did not translate into the same balance-sheet cushion; reported liquidity equaled only 1.8 months of the latest annual outflow.

FY2025 financing cash flow of $5.7M was slightly greater than operating cash outflow of $5.2M, while investing cash flow used $3.0M. External funding, rather than internally generated cash, financed both operations and investment during the year.

The net loss narrowed from $11.5M in FY2024 to $7.0M in FY2025, while operating cash outflow was smaller than the accounting loss. This gap suggests non-cash expenses and working-capital effects softened cash usage, but earnings still did not convert into positive operating cash.

Financial Health Signals

Financial health score not available

ENDRA Life Sciences Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

ENDRA Life Sciences Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing

N/A

ENDRA Life Sciences Inc. reported a net loss of $7.0M while operations used $5.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$1.5M

YoY-14.2%

QoQ+31.8%

ENDRA Life Sciences Inc.'s EBITDA was -$1.5M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 14.2% from the same quarter a year earlier. Against the prior quarter it is up 31.8%.

Net Income

$160K

YoY+113.0%

QoQ+112.2%

ENDRA Life Sciences Inc. reported $160K in net income in Q2 2026. This represents an increase of 113.0% from the same quarter a year earlier. Against the prior quarter it is up 112.2%.

EPS (Diluted)

$0.06

ENDRA Life Sciences Inc. earned $0.06 per diluted share (EPS) in Q2 2026.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$1.7M

YoY-3.8%

QoQ+388.1%

5Y CAGR-34.1%

10Y CAGR+13.2%

ENDRA Life Sciences Inc. held $1.7M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

5Y CAGR-48.6%

ENDRA Life Sciences Inc. had 1M shares outstanding in Q2 2026.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

2.5%

YoY+85.8pp

QoQ+75.9pp

ENDRA Life Sciences Inc.'s ROE was 2.5% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 85.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 75.9 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$234K

YoY-38.7%

QoQ-69.9%

ENDRA Life Sciences Inc. invested $234K in research and development in Q2 2026. This represents a decrease of 38.7% from the same quarter a year earlier. Against the prior quarter it is down 69.9%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

NDRA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NDRA quarterly income statement

Metric	TTM	FY25S-4	FY24S-4	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$6K-98.2%	$352K-31.8%	$516K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	$0-100.0%	$173K	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$6K-96.5%	$179K-36.1%	$280K
R&D Expenses	N/A	$1.8M-42.0%	$3.2M-36.2%	$5.0M-23.7%	$6.6M+19.5%	$5.5M-7.4%	$5.9M-10.0%	$6.6M+39.2%	$4.7M+144.6%	$1.9M+289.8%	$495K
SG&A Expenses	N/A	$3.7M-47.2%	$7.1M+50.2%	$4.7M-9.2%	$5.2M+4.7%	$4.9M-1.2%	$5.0M+29.7%	$3.9M+2.8%	$3.8M+36.4%	$2.8M+78.4%	$1.5M
Operating Income	N/A	-$5.8M+46.7%	-$10.8M-2.8%	-$10.5M+20.0%	-$13.2M-14.4%	-$11.5M0.0%	-$11.5M-6.1%	-$10.8M-20.2%	-$9.0M-95.0%	-$4.6M-158.2%	-$1.8M
EBITDA	N/A	-$5.7M+46.9%	-$10.8M-3.6%	-$10.4M+20.4%	-$13.1M-14.7%	-$11.4M+0.2%	-$11.4M-5.9%	-$10.8M-20.2%	-$9.0M-96.1%	-$4.6M-164.3%	-$1.7M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$43K-40.8%	$72K
Income Tax	N/A	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	N/A	-$7.0M+38.9%	-$11.5M-14.4%	-$10.1M+23.7%	-$13.2M-17.3%	-$11.2M+4.2%	-$11.7M+11.9%	-$13.3M-35.8%	-$9.8M-82.2%	-$5.4M	N/A
EPS (Basic)	N/A	-$8.93+84.3%	-$56.94	N/A	-$4.56+17.8%	-$5.55-781.0%	-$0.63	N/A	N/A	N/A	N/A
EPS (Diluted)	-$6.38	-$8.93	-$56.94	-$2766.85	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	787,020	202,106	3,636	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26S-4	Q1'2610-Q	Q4'25S-4	Q3'2510-Q	Q2'25S-4	Q1'2510-Q	Q4'24S-4	Q3'2410-Q
R&D Expenses	$234K-38.7%	$776K+46.9%	N/A	$432K-45.6%	$381K-46.8%	$529K-49.2%	N/A	$794K-51.3%
SG&A Expenses	$1.2M+46.1%	$1.4M+59.8%	N/A	$893K+41.5%	$851K-37.0%	$872K-41.9%	N/A	$631K-49.6%
Operating Income	-$1.5M-14.0%	-$2.2M-47.9%	N/A	-$1.4M+9.2%	-$1.3M+41.7%	-$1.5M+47.2%	N/A	-$1.5M+51.8%
EBITDA	-$1.5M-14.2%	-$2.2M-48.7%	N/A	-$1.4M+9.2%	-$1.3M+41.9%	-$1.5M+47.4%	N/A	-$1.5M+51.6%
Income Tax	$0	N/A	N/A	N/A	$0	$0	N/A	$0
Net Income	$160K+113.0%	-$1.3M-26.5%	N/A	-$1.6M+32.2%	-$1.2M+45.0%	-$1.0M+62.7%	N/A	-$2.4M+24.1%
EPS (Basic)	$0.12+107.0%	-$1.09+41.4%	-$3.25-112.9%	-$2.10+78.0%	-$1.71	-$1.86	$25.20	-$9.54
EPS (Diluted)	$0.06	-$1.09	-$3.25	-$2.10	-$1.71	-$1.86	$25.20	-$9.54
Diluted Shares (Avg)	2M	1M	N/A	761,218	717,107	557,582	N/A	246,816

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.

NDRA Balance Sheet

NDRA quarterly balance sheet

Metric	FY25S-4	FY24S-4	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Total Assets	$3.9M-13.4%	$4.5M-34.1%	$6.8M-27.2%	$9.3M-28.0%	$12.9M+46.9%	$8.8M+22.1%	$7.2M-0.6%	$7.2M+17.9%	$6.1M+1147.8%	$491K
Current Assets	$968K-71.8%	$3.4M+13.2%	$3.0M-43.6%	$5.4M-55.5%	$12.1M+47.4%	$8.2M+25.6%	$6.5M-6.0%	$6.9M+18.1%	$5.9M+2907.3%	$196K
Cash & Equivalents	$762K-76.4%	$3.2M+14.0%	$2.8M-42.0%	$4.9M-48.3%	$9.5M+30.9%	$7.2M+17.1%	$6.2M-4.6%	$6.5M+15.5%	$5.6M+3764.6%	$145K
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$0	$0-100.0%	$2.6M-0.8%	$2.6M+105.9%	$1.3M+117.9%	$590K+419.8%	$113K+90.8%	$59K-69.0%	$192K+377.9%	$40K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$7K	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$1.6M-15.8%	$1.9M+72.8%	$1.1M-47.1%	$2.1M-1.0%	$2.1M+31.0%	$1.6M-33.9%	$2.4M+147.9%	$975K+14.9%	$848K-38.7%	$1.4M
Current Liabilities	$751K+24.1%	$605K-33.0%	$903K-47.0%	$1.7M+10.4%	$1.5M+56.5%	$987K-52.4%	$2.1M+112.7%	$975K+14.9%	$848K-38.7%	$1.4M
Non-Current Liabilities	$843K-34.5%	$1.3M+570.0%	$192K-47.5%	$366K-33.1%	$547K-10.2%	$609K+77.6%	$343K	$0	$0	$0
Long-Term Debt	N/A	$0	$0	$0-100.0%	$547K	N/A	N/A	N/A	N/A	N/A
Total Equity	$2.3M-11.7%	$2.6M-54.8%	$5.7M-21.5%	$7.2M-33.2%	$10.8M+50.4%	$7.2M+50.6%	$4.8M-23.8%	$6.2M+18.4%	$5.3M+690.3%	-$894K
Retained Earnings	-$110.5M-6.8%	-$103.4M-12.5%	-$91.9M-12.3%	-$81.9M-19.2%	-$68.7M-19.8%	-$57.3M-26.8%	-$45.2M-63.3%	-$27.7M-54.7%	-$17.9M-43.0%	-$12.5M

Metric	Q2'26S-4	Q1'2610-Q	Q4'25S-4	Q3'2510-Q	Q2'25S-4	Q1'2510-Q	Q4'24S-4	Q3'2410-Q
Total Assets	$7.9M+182.9%	$3.4M+8.4%	$3.9M-13.4%	$2.0M-76.6%	$2.8M-73.1%	$3.2M-37.3%	$4.5M-34.1%	$8.4M+10.2%
Current Assets	$5.6M+201.5%	$537K-75.4%	$968K-71.8%	$1.0M-78.9%	$1.9M-72.4%	$2.2M+71.6%	$3.4M+13.2%	$5.0M-22.4%
Cash & Equivalents	$1.7M-3.8%	$356K-82.7%	$762K-76.4%	$794K-83.3%	$1.8M-71.7%	$2.1M+82.0%	$3.2M+14.0%	$4.7M+42.3%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	N/A	N/A	$0	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%	$2.7M-1.7%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$1.6M+22.3%	$1.7M+16.5%	$1.6M-15.8%	$1.8M+1.0%	$1.3M-7.9%	$1.4M+4.1%	$1.9M+72.8%	$1.8M-26.3%
Current Liabilities	$787K+36.4%	$835K+47.7%	$751K+24.1%	$800K-1.7%	$577K-57.3%	$566K-53.5%	$605K-33.0%	$814K-62.5%
Non-Current Liabilities	$846K+11.6%	$816K-4.2%	$843K-34.5%	$992K+3.3%	$758K+670.0%	$852K+484.2%	$1.3M+570.0%	$960K+304.9%
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	$0	N/A
Total Equity	$6.3M+328.3%	$1.8M+1.9%	$2.3M-11.7%	$171K-97.4%	$1.5M-83.6%	$1.8M-52.6%	$2.6M-54.8%	$6.6M+27.1%
Retained Earnings	-$111.6M-5.6%	-$111.8M-7.0%	-$110.5M-6.8%	-$107.3M-8.1%	-$105.7M-9.0%	-$104.5M-10.3%	-$103.4M-12.5%	-$99.3M-9.7%

Not reported in any period shown, so not listed: Accounts Receivable, Goodwill.

NDRA Cash Flow Statement

NDRA quarterly cash flow statement

Metric	TTM	FY25S-4	FY24S-4	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Operating Cash Flow	-$4.8M	-$5.2M+30.0%	-$7.4M+22.5%	-$9.5M+25.2%	-$12.8M-14.8%	-$11.1M-3.5%	-$10.7M-25.1%	-$8.6M-11.5%	-$7.7M-133.3%	-$3.3M-150.9%	-$1.3M
Depreciation & Amortization	N/A	$44K-5.3%	$46K-62.4%	$124K+28.0%	$97K-16.8%	$116K+17.0%	$99K+23.3%	$81K+17.9%	$68K+11.1%	$61K-5.3%	$65K
Stock-Based Compensation	N/A	$329K-42.4%	$572K-42.6%	$996K-17.0%	$1.2M-16.9%	$1.4M-31.3%	$2.1M	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	$17K+8.0%	$16K-52.8%	$34K-83.3%	$203K+350.2%	$45K-40.3%	$75K+72.8%	$44K-56.4%	$100K+1171.9%	$8K	N/A
Free Cash Flow	N/A	-$5.2M+29.9%	-$7.4M+22.6%	-$9.6M+26.1%	-$13.0M-16.2%	-$11.2M-3.2%	-$10.8M-25.4%	-$8.6M-10.6%	-$7.8M-135.8%	-$3.3M	N/A
Investing Cash Flow	-$333K	-$3.0M-23479.9%	-$13K+48.2%	-$25K+87.8%	-$203K-350.2%	-$45K+40.3%	-$75K-72.8%	-$44K+56.4%	-$100K-1171.9%	-$8K	$0
Financing Cash Flow	$8.9M	$5.7M-26.6%	$7.8M+3.9%	$7.5M-10.5%	$8.4M-37.3%	$13.4M+12.9%	$11.9M+42.5%	$8.3M-3.9%	$8.7M-1.1%	$8.8M+508.1%	$1.4M
Dividends Paid	N/A	N/A	N/A	N/A	$0-100.0%	$121K-69.4%	$396K-90.6%	$4.2M	$0	N/A	N/A

Metric	Q2'26S-4	Q1'2610-Q	Q4'25S-4	Q3'2510-Q	Q2'25S-4	Q1'2510-Q	Q4'24S-4	Q3'2410-Q
Operating Cash Flow	-$928K+16.7%	-$1.1M+13.4%	-$1.6M-6.3%	-$1.2M+29.8%	-$1.1M+46.5%	-$1.3M+39.7%	-$1.5M+30.3%	-$1.7M+36.2%
Depreciation & Amortization	$8K-12.8%	$9K-31.1%	$10K-8.0%	$11K-6.2%	$9K+7.6%	$14K-9.9%	$11K-49.7%	$11K-64.1%
Stock-Based Compensation	N/A	$574K+591.7%	N/A	N/A	$40K	$83K-73.8%	N/A	N/A
Capital Expenditures	N/A	N/A	$0	$0	$0-100.0%	$17K-36.0%	$0-100.0%	$0
Free Cash Flow	N/A	N/A	-$1.6M-6.3%	-$1.2M+29.8%	-$1.1M+46.8%	-$1.3M+39.6%	-$1.5M+30.5%	-$1.7M+36.2%
Investing Cash Flow	$2.2M	$450K+2704.2%	-$3.0M	$0	$0-100.0%	-$17K+27.4%	$0-100.0%	$0
Financing Cash Flow	$3.9M+354.1%	$264K+80.9%	$4.6M	$149K+8780.9%	$857K-88.3%	$146K-68.9%	$0-100.0%	$2K-99.8%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

NDRA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NDRA quarterly financial ratios

Metric	FY25S-4	FY24S-4	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	100.0%+49.1pp	50.9%-3.4pp	54.3%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-146080.5%	-1315.6%	-347.5%
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-158669.6%	-1529.2%	N/A
Return on Equity	-310.9%+138.5pp	-449.5%-271.7pp	-177.8%+5.2pp	-182.9%-78.8pp	-104.1%+59.4pp	-163.5%+116.0pp	-279.5%-122.7pp	-156.8%-54.9pp	-101.9%	N/A
Return on Assets	-182.3%+76.1pp	-258.5%-109.5pp	-149.0%-6.8pp	-142.1%-54.9pp	-87.2%+46.5pp	-133.8%+51.6pp	-185.4%-49.8pp	-135.6%-47.8pp	-87.8%	N/A
Current Ratio	1.29-4.4x	5.67+2.3x	3.36+0.2x	3.16-4.7x	7.83-0.5x	8.32+5.2x	3.15-4.0x	7.13+0.2x	6.93+6.8x	0.14
Debt-to-Equity	0.71+0.7x	0.000.0x	0.000.0x	0.00-0.1x	0.05-0.2x	0.22-0.3x	0.51+0.4x	0.160.0x	0.16	N/A
Asset Turnover	N/A	N/A	N/A	N/A	N/A	0.000.0x	0.000.0x	0.00-0.1x	0.06-1.0x	1.05
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-126376.4%	-941.0%	N/A

Metric	Q2'26S-4	Q1'2610-Q	Q4'25S-4	Q3'2510-Q	Q2'25S-4	Q1'2510-Q	Q4'24S-4	Q3'2410-Q
Return on Equity	2.5%+85.8pp	-73.4%-14.3pp	N/A	-931.2%-895.6pp	-83.2%-58.4pp	-59.1%+15.9pp	N/A	-35.6%+24.0pp
Return on Assets	2.0%+45.7pp	-38.1%-5.4pp	N/A	-81.3%-53.2pp	-43.7%-22.3pp	-32.7%+22.2pp	N/A	-28.1%+12.7pp
Current Ratio	7.10+3.9x	0.64-3.2x	1.29-4.4x	1.31-4.8x	3.21-1.8x	3.85+2.8x	5.67+2.3x	6.10+3.1x
Debt-to-Equity	0.26-0.6x	0.92+0.1x	0.71+0.7x	10.46+10.2x	0.91+0.7x	0.81+0.8x	0.000.0x	0.27-0.2x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
ENDRA Life Sciences Inc. NDRA	FY2025	N/A	-$7.0M	N/A	$7.6M	—
Check-Cap Ltd. CHEK	FY2025	N/A	$4.1M	N/A	$9.4M	—
Applied DNA Sciences, Inc. APDN	FY2025	$2.1M	-$15.2M	N/A	$7.3M	27/100
bioAffinity Technologies, Inc. BIAF	FY2025	$6.2M	-$14.9M	N/A	$2.3M	45/100
Mainz Biomed N.V. MYNZ	FY2025	$537K	-$16.2M	N/A	$10.6M	—
XWELL, Inc. XWEL	FY2025	$29.2M	-$17.0M	-58.2%	$8.2M	28/100

Where ENDRA Life Sciences Inc. Ranks

Frequently Asked Questions

Is ENDRA Life Sciences Inc. profitable?

No, ENDRA Life Sciences Inc. (NDRA) reported a net income of -$7.0M in fiscal year 2025.

What is ENDRA Life Sciences Inc.'s EBITDA?

ENDRA Life Sciences Inc. (NDRA) had EBITDA of -$5.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is ENDRA Life Sciences Inc.'s return on equity (ROE)?

ENDRA Life Sciences Inc. (NDRA) has a return on equity of -310.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is ENDRA Life Sciences Inc.'s free cash flow?

ENDRA Life Sciences Inc. (NDRA) recorded an outflow of $5.2M in free cash flow during fiscal year 2025. This represents a 29.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is ENDRA Life Sciences Inc.'s operating cash flow?

ENDRA Life Sciences Inc. (NDRA) recorded an outflow of $5.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are ENDRA Life Sciences Inc.'s total assets?

ENDRA Life Sciences Inc. (NDRA) had $3.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are ENDRA Life Sciences Inc.'s capital expenditures?

ENDRA Life Sciences Inc. (NDRA) invested $17K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does ENDRA Life Sciences Inc. spend on research and development?

ENDRA Life Sciences Inc. (NDRA) invested $1.8M in research and development during fiscal year 2025.

How many shares does ENDRA Life Sciences Inc. have outstanding?

ENDRA Life Sciences Inc. (NDRA) had 1M shares outstanding as of fiscal year 2025.

What is ENDRA Life Sciences Inc.'s current ratio?

ENDRA Life Sciences Inc. (NDRA) had a current ratio of 1.29 as of fiscal year 2025, which is considered adequate.

What is ENDRA Life Sciences Inc.'s debt-to-equity ratio?

ENDRA Life Sciences Inc. (NDRA) had a debt-to-equity ratio of 0.71 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is ENDRA Life Sciences Inc.'s return on assets (ROA)?

ENDRA Life Sciences Inc. (NDRA) had a return on assets of -182.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is ENDRA Life Sciences Inc.'s P/E ratio?

ENDRA Life Sciences Inc. (NDRA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $7.6M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is ENDRA Life Sciences Inc.'s price-to-sales ratio?

ENDRA Life Sciences Inc. (NDRA) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $7.6M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does ENDRA Life Sciences Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, ENDRA Life Sciences Inc. (NDRA) held $762K in cash, cash equivalents and investments, and reported an operating cash outflow of $5.2M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is ENDRA Life Sciences Inc.'s Piotroski F-Score?

ENDRA Life Sciences Inc. (NDRA) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are ENDRA Life Sciences Inc.'s earnings high quality?

ENDRA Life Sciences Inc. (NDRA) reported a net loss of $7.0M while operations used $5.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.